This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and
pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
Hospitalized subjects with influenza A or B that have either a low oxygen level or a high
respiratory rate will be eligible for study participation. This study will enroll adults,
children and pregnant women.